Granulocyte colony-stimulating factor (G-CSF) is widely used to reduce the duration of neutropenia after cytotoxic therapy. A number of randomized studies have demonstrated that G-CSF and GM-CSF can also hasten neutrophil recovery after high-dose chemotherapy (HDT) and transplantation of autologous bone marrow (BM) [1] [2] [3] or peripheral blood progenitor cells (PBPC). [4] [5] [6] [7] [8] [9] Convincing evidence, however, that the administration of G-CSF significantly alters the clinical course of patients undergoing HDT is limited. To address this latter question, we initiated a large phase III trial which randomized patients to receive lenograstim (glycosylated recombinant human G-CSF) or placebo after PBPCT. The incidence of microbiologically documented infections occurring before neutrophil recovery was chosen as the primary end point of the study because infections are the leading cause of nonrelapse morbidity and mortality after autologous PBPCT. 10, 11 The overall incidence of infections and other clinically important parameters such as the use of i.v. antibiotics, the numbers of red blood cell (RBC) and platelet transfusions, the days on parenteral nutrition, and the days spent in hospital were also compared.
Patients and methods

Study design
This was a phase III, prospective, randomized, doubleblind, placebo-controlled, multi-center trial conducted between February 1998 and June 2000 in 20 institutions in Europe (see the appendix). The trial was designed to investigate the effect of lenograstim on the incidence of infections occurring until neutrophil recovery after autologous PBPCT.
The study was approved by the ethics committee at each participating institution and written informed consent was obtained from all patients. After verification of inclusion and exclusion criteria, patients were assigned a unique patient number and treatment started as per protocol. Randomization to lenograstim or placebo after PBPCT was carried out centrally at the sponsor's office using clinpro software when high-dose therapy was initiated. Randomization was stratified by the number of lines of prior chemotherapy and the use of prophylactic quinolones.
Patient eligibility
Patients with a WHO performance status p2 between 16 and 65 years of age were eligible to participate if they suffered from Hodgkin's disease, non-Hodgkin's lymphoma (NHL), multiple myeloma, breast cancer or any other solid tumor where HDT and autologous PBPCT were planned. Exclusion criteria were any of the following: chemoresistant progressive disease, absolute neutrophil count (ANC) o1.5 Â 10 9 /l, and/or thrombocytopenia o100 Â 10 9 /l under steady-state conditions, serum bilirubin and/or creatinine 41.25 times than the upper limit of the normal value (N); AST and/or ALT 42.5 times N; known allergy to growth factors or other recombinant products. Patients with any disorder (cardiovascular, neurological, hepatic, renal etc.) deemed to interfere with the study conduct and pregnant or lactating women were also excluded.
Treatment
The treatment protocol is shown in Figure 1 . Patients enrolled had a complete history and physical examination; a complete blood count and biochemistry profile, ECG, chest X-ray and other appropriate tests necessary to evaluate the patient's performance status and disease activity were performed. The mobilization procedure consisted of disease-specific chemotherapy, followed by the administration of lenograstim given subcutaneously at a dose of 150 mg/m 2 of body surface per day until the end of collections. A maximum of three leukaphereses on consecutive days was allowed in order to harvest X2.0 Â 10 6
CD34
þ cells/kg body weight. Patients not achieving this target cell yield were withdrawn from the study. Leukapheresis products were cryopreserved according to standard procedures.
HDT was commenced no later than 3 months after the last leukapheresis. Before HDT physical examination, hematology and biochemistry tests were repeated, and vital signs were recorded. The regimen of high-dose therapy followed the patient's diagnosis and status of disease; only established myeloablative regimes could be used (see Table 1 ). The cryopreserved PBPCs were thawed and reinfused no later than 72 h after completion of high-dose therapy. The day of reinfusion was designated day 0. On day þ 1 after transplantation, subcutaneous administration of lenograstim (150 mg/m 2 ) or placebo was started. Lenograstim or placebo were sent to the investigator as lyophilized white powder (CHUGAI-AVENTIS, Antony, France); the blinded study drug was reconstituted with 1 ml of sterile water and administered once daily in the morning, until neutrophil recovery as defined below occurred.
Clinical monitoring and safety
Vital signs including body temperature, complete blood counts, blood chemistry and medication were monitored daily during leukapheresis and hospital stay and -if necessary -repeated at any time following discharge. Follow-up visits were scheduled 1 and 4 weeks following the last dose of lenograstim.
Safety analyses were performed on the intent-to-treat population during the time period from day 0 to the end of study. Adverse events, serious adverse events, and deaths were recorded and compared between treatment groups.
Infections and supportive care
This study was specifically designed to investigate the influence of lenograstim administration on the incidence, type, and severity of infections occurring after high-dose therapy and transplantation of autologous PBPCs. The following guidelines are based on discussions with the investigators at various study sites and the principal investigator. Patients were carefully observed for any type of infection throughout the study. Fever and any clinical symptoms, their onset, duration, treatment, and outcome were documented daily. Fever was defined as an oral temperature 438.51C once or 438.01C on X2 occasions during a 12-h period. In febrile patients, temperature was to be recorded at least twice daily until it returned to p38.01C. If an infectious episode was suspected, the following examinations were to be performed: complete physical examination, chest X-ray (frontal and lateral view), and blood cultures for aerobes and anaerobes. In addition, stool, urine, sputum, swabs from suspect sites, and other materials were to be collected if clinically indicated.
An infection was diagnosed if clinical signs or symptoms and/or the respective laboratory tests led to a diagnosis of infection that necessitated specific treatment. Following recommendations of the Immuno-Compromised Host Society, 12 infections were characterized according to the following criteria:
A. Microbiologically defined infections:
A1. bacteremia, with one or more organisms, but without a definable nonhematogenous site of infection; A2. microbiologically defined site of infection (eg pneumonia, cellulitis) with or without concomitant bacteremia. B. Clinically defined infection: a site of infection was diagnosed, but its microbiological pathogenesis was either unclear, could not be proven or was inaccessible to examination. C. Unexplained fever: a new fever that was not accompanied by either clinical or microbiologic evidence of infection.
A and B infections included bacteremia, pneumonia, enteritis, urinary tract infection, stomatitis, catheter infection, viral, and other infections.
When repeated microbiological/virological analyses failed to detect the responsible pathogen, but there were strong clinical features of an infection, it was classified as clinically defined infection (B).
Serious infections were defined as infections requiring hospitalization or prolonged hospitalization; life-threatening infections were those leading to significant disability or death.
Decontamination of the gut using nonabsorbable antibiotics, as well as antifungal and antiviral prophylaxis with aciclovir, was allowed. Patients were stratified by the use of prophylactic quinolones (see study design). Prophylactic administration of cotrimoxazole was not allowed.
Any approved broad-spectrum antibiotic(s) could be used for empirical treatment of a newly diagnosed infection. Results of antibiotic sensitivity testing, site, and clinical course of the infection were taken into account and could trigger off a modification of the antibiotic regimen. The following criteria had to be met if termination of antibiotic therapy was considered:
1. For clinically and/or microbiologically documented infections: apyrexia, an improving or resolving clinical infection and a stable ANC 41.0 Â 10 9 /l for 3 consecutive days. A new sample for microbiological analysis was also mandatory.
For unexplained fever:
a. apyrexia and ANC 41.0 Â 10 9 /l for 3 consecutive days, or b. apyrexia for 5 consecutive days (7 days if amphotericin was given) regardless of ANC.
Details of infectious prophylaxis (number of days and type of prophylaxis) were recorded daily. Antibiotic and antifungal therapies were monitored in detail (drug, dosage, start, and duration of treatment).
Platelet and red blood cell transfusions and days with parenteral nutrition were documented.
Infectious disease review
An independent expert (CC) not involved in the planning, conduct, and analysis of the study reviewed all episodes defined by the investigators as microbiologically documented infections. The expert had access to the case report forms, but was blinded to patient and institutional details as well as the treatment arm (lenograstim or placebo) of the individual patient.
Study end points and definitions
The primary end point of this study was the incidence of microbiologically defined infections occurring before neutrophil recovery after PBPCT in both arms. We wanted to decrease the rate of documented infections from 45 to 25%. Secondary end points were the incidence, severity, and duration of all infections classified according to the categories given above, the number of days on i.v. antibiotics, the use of blood products and parenteral nutrition, the times to hematological recovery, and the duration of hospitalization. Recovery of the ANC was defined as the number of days from PBPC infusion (day 0) until the first day when the neutrophil count exceeded 0.5 Â 10 9 /l for 3 consecutive days or 1.0 Â 10 9 /l for 1 day. Time to platelet independence was defined as the number of days from day 0 to the first of three consecutive days with an unsupported platelet count 420 Â 10 9 /l. Duration of hospitalization was defined as the number of days spent in hospital from day þ 1 after infusion of PBPCs until discharge. Discharge from hospital could only occur if the patient had recovered his/her ANC, was afebrile, did not show any signs of infection, and was not being treated with i.v. antibiotics/antifungals, or parenteral nutrition.
Statistical analysis
The study was powered to detect a difference of at least 20% in the cumulative incidence of microbiologically documented infections (A1 or A2), occurring until neutrophil recovery after PBPCT, assuming an incidence of 45% in the placebo group with a ¼ 0.05 and (1Àb) ¼ 0.80.
The cumulative incidence of infections of a given type after PBPCT was defined as the number of patients who experienced at least one infection of this type between PBPCT and recovery from neutropenia, divided by the number of patients at risk. The incidence was expressed as a percentage and compared among treatment groups using Fisher's exact test. Median times to clinical events (eg time to neutrophil recovery) were determined using the nonparametric Kaplan-Meier estimations; survival curves were compared among treatment groups using the log-rank test. Quantitative parameters were compared with the KruskalWallis test. All reported P-values are based on two-sided tests with no correction for multiplicity of tests. Analyses were performed using the SAS package (version 6.12).
Results
Patients
A total of 307 patients fulfilled the inclusion criteria; they received disease-specific mobilizing chemotherapy, followed by the administration of lenograstim (150 mg/m 2 / day) given s.c. until the day of last leukapheresis. Of these, 115 patients did not proceed to high-dose therapy and randomization because they progressed (26 patients), the therapeutic strategy was modified due to disease evolution (six patients), the target cell number of CD34 þ cells in the collection product was not reached (36 patients), or collection was not attempted because of low CD34 þ cell concentrations in peripheral blood (11 patients). Further patients were excluded from randomization because of a delay between PBPC mobilization and transplantation exceeding 3 months (five patients), other protocol violations (four patients) or adverse events (eight patients). Four patients withdrew consent, six patients were excluded due to the treating physician's decision. Contamination of the graft by tumor cells or infectious agents was the cause of withdrawal in three and one patients, respectively. Five patients were excluded because of logistical reasons.
A total of 192 patients were randomized and represent the intent-to-treat population subsequently analyzed. The characteristics of these patients are summarized in Table 2 . In all, 16 patients were not eligible for the study because they had received growth factor prior to inclusion (n ¼ 7), had received prophylactic co-trimoxazole (n ¼ 7), or had not received study drug as per the protocol (n ¼ 2). Thus, 176 patients remained eligible, with 88 patients each receiving lenograstim or placebo after PBPCT.
Prophylaxis of infections
Antifungal prophylaxis with fluconazol was administered to 53.2% of patients in the placebo group and 59.2% patients in the lenograstim group (P ¼ 0.467). Antibiotic prophylaxis (mainly quinolones) was given to 75.5% of patients on placebo and 75.5% of patients on lenograstim; two patients in each treatment arm received prophylactic vancomycin. In all, 45.7% of patients randomized to placebo and 45.9% of patients randomized to lenograstim received prophylactic oral aciclovir (P40.999).
Infectious episodes
The total number of patients with at least one infection during neutropenia after PBPCT is given in Table 3 . Patients who received lenograstim after transplantation experienced significantly fewer infections than those given placebo (Po0.001). Table 3 also shows that fewer patients on lenograstim suffered from clinically defined infections (category B) and neutropenic fever (category C); however, differences were significant only for microbiologically defined (A1 and A2) infections. Fewer patients with bacteremia (Po0.001) were observed in the lenograstim arm, while differences in all other categories (unexplained fever, pneumonia, enteritis, urinary tract infections, stomatitis, catheter infections and other) were not significantly different. The organisms found to cause microbiologically defined infections are listed in Table 4 . More patients in the placebo arm experienced coagulase-negative staphylococcus (CNS) infections. Excluding the patients with only one CNS-positive blood culture, since these might have been due to contamination rather than true infections, the incidence of microbiologically documented infections until recovery remains lower in the lenograstim group (19 vs 26 patients, P ¼ 0.004). Furthermore, if all patients with CNSpositive blood cultures only are excluded, there was still a significantly higher incidence of microbiologically defined infections in the placebo arm (P ¼ 0.042).
Severe and life-threatening infections were rare in both groups of patients. In the lenograstim group, five infections were classified as severe and four infections were considered life-threatening; in the placebo group, five severe and two life-threatening infections were observed. These differences were not significant. One patient given lenograstim and one patient given placebo died of aspergillus pneumonia.
The time from infusion of PBPC to the first microbiologically defined infection was significantly longer in the lenograstim group compared to the placebo group (P ¼ 0.001) (see Figure 2) . The median duration of infection was 8 days (range: 1-54) in the placebo group and 6 days (range: 1-21) in the lenograstim group (P ¼ 0.15).
In all, 29 patients given lenograstim post PBPCT experienced at least one microbiologically defined (A1 or A2) infection as opposed to 45 patients in the placebo group if the whole study period (prior to and after neutrophil recovery) was considered (P ¼ 0.012).
Infections validated by review
The independent expert (CC) reviewed all microbiologically defined infections as reported by the investigators of the participating centers. At the time of the review, investigators and reviewer knew the overall results of the study; however, the expert did not know if a particular patient had received lenograstim or placebo when reviewing the case report forms. In total, 19 infections in the lenograstim arm and 43 infections in the placebo arm were confirmed. This resulted in an incidence of validated infections of 18.4% (18 of 98 patients) in the lenograstim group and 45.7% (43 of 94 patients) in the placebo group (Po0.001).
Hematopoietic recovery
The median number of leukaphereses performed in patients on the placebo or lenograstim arm of the study was two (range [1] [2] [3] [4] [5] . A median number of 4.1 Â 10 6 CD34 þ cells/kg body weight (range: 1.9-38.1) were reinfused to patients in the placebo group and 4.4 Â 10 6 CD34 þ cells/kg (range: 2.0-18.2) were reinfused to patients in the lenograstim group. After reinfusion of the harvest products, the median time to neutrophil recovery was 11 days (95% confidence interval (CI) 10-11 days) in the patients treated with lenograstim and 15 days (95% CI 14-16) in patients treated with placebo after transplantation (Po0.001). The median time to platelet independence was 15 days (95% CI [13] [14] [15] [16] in the lenograstim and 13 days (95 % CI 12-13) in the placebo group (P ¼ 0.33). There were no significant differences in the numbers of RBC or platelet transfusions given after PBPCT.
Use of i.v. antibiotics
In the placebo group, 90.4% of patients needed treatment with i.v. antibiotics compared with 67.3% of patients randomized to lenograstim (Po0.001). The median duration of i.v. antibiotic treatment was 10 days (range: 2-46 days) in the placebo group and 8 days (range: 2-42 days) in the lenograstim group (P ¼ 0.04).
Hospitalization and parenteral nutrition
The median duration of hospitalization was 17 days (range: 11-46) in the placebo group and 15 days (range: 4-44) in the lenograstim group (Po0.001).
There was no statistical difference in the percentage of patients who needed parenteral nutrition on study (40.4% in the placebo group and 36.7% in the lenograstim group, respectively).
Causes of death
Two patients given placebo and four patients given lenograstim after transplantation died before the end of the study (day þ 60). Table 5 describes the time and causes of death in detail. Table 3 Incidence of infections a after PBPCT until neutrophil recovery
Intent-to-treat Eligible
Placebo N (%) Lenograstim N (%) P Placebo N (%) Lenograstim N (%) P 
Safety analysis
Lenograstim administration after transplantation of PBPC was well tolerated. There was no difference in the overall frequency of adverse or severe adverse events between patients given lenograstim or placebo until the end of the study.
Discussion
Numerous retrospective analyses and a number of randomized studies have shown that the administration of G-CSF after autologous BMT [1] [2] [3] or PBPCT 4-9 can significantly accelerate neutrophil recovery. Based on these findings, the American Society of Clinical Oncology and the Haemato-Oncology Task Force of the British Committee for Standards in Haematology recommend the use of G-CSF after high-dose therapy and autologous PBPCT. 13, 14 With respect to important clinical end points such as the incidence of infections, the use of i.v. antibiotics, the number of days spent in hospital, red blood cell, and platelet transfusion requirements, and the need for parenteral nutrition, the randomized studies have shown equivocal results and most have been negative, that is, they were unable to demonstrate a clinical benefit of growth factor administration after transplantation of hematopoietic stem cells.
Here, we demonstrate that the use of lenograstim after autologous PBPCT significantly reduces the overall incidence of infections and specifically of microbiologically defined infections in a large cohort of patients with lymphomas or solid tumors. The difference in the incidence of infections was restricted to microbiologically defined (A1 or A2) infections; these infections were clinically mild or moderate in most instances; severe and life-threatening infections were rare in both groups of patients.
The clearest difference was seen for infections with CNS. As in other studies including patients undergoing aggressive chemotherapy or autologous transplantation for hematological malignancies, 15, 16 about one-third of all infections diagnosed in our patients were with CNS. Although usually not clinically severe or life-threatening, these infections cause practical problems as CNS colonize central venous catheters, but are also common in the gastro-intestinal tract. The shorter duration of neutropenia in patients treated with lenograstim was most likely associated with a shorter duration of mucosal damage, which might have been associated with the shorter time an indwelling central venous line was deemed necessary. Both factors might have contributed to the lower rate of infections with CNS. Reasons other than lenograstim might be considered to explain the differences in CNS infections seen between the Table 4 Pathogens causing microbiologically defined (A1 and A2) infections prior to neutrophil recovery
Placebo Lenograstim
Coagulase-negative staphylococci (25 patients) Coagulase-negative staphylococci (seven patients) Staphylococcus aureus (one patient)
Staphylococcus aureus (one patient) Staphylococcus, not otherwise specified (one patient) Staphylococcus, not otherwise specified (one patient) E. coli (six patients) E. coli (three patients) Streptococcus mitis (two patients)
Streptococcus mitis (one patient) Streptococcus viridans (three patients)
Streptococcus viridans (one patient) Streptococcus, not otherwise specified (two patients) Streptococcus, not otherwise specified (one patient) Pneumococcus (two patients)
Streptococcus anginosus (one patient) Enterococcus faecium or faecalis (five patients)
Streptococcus oralis (one patient) Enterococcus, not otherwise specified (five patients) Enterococcus, not otherwise specified (three patients) Eikenella corrodens (one patient) Gemella sp. (one patient) Giardia lamblia (one patient)
Pseudomonas aeruginosa (one patient) Blastocystis hominis (one patient)
Ralstonia pickettii (one patient) Acinetobacter Baumanni (one patient)
Enterobacter cloacae (one patient) Diphteroids (one patient) Klebsiella oxitr. (one patient) Corynebacterium (one patient) Prevotella denticola (one patient) Clostridium difficile (one patient) Candida krusei (one patients)
Candida albicans (one patient) Candida glabrata (one patient)
Aspergillus fumigatus (one patient) Yeasts (non Candida albicans) (one patient)
Herpes simplex (one patient)
Infection numbers exceed total number of patients with infections because some patients had more than one pathogen detected simultaneously. Lenograstim after autologous transplantation N Schmitz et al treatment arms. Differences in prophylactic administration of antibiotics effective against CNS infections did not exist and cannot explain our findings. Although we do not have complete information on the type of catheters used, their day-to-day management, or other subtle differences in patient care, it seems highly unlikely that these account for the differences in CNS infections, because this was a double-blind study and we formally looked for center effects and could not detect any. What are the reasons for our finding that the overall incidence of infections was reduced by lenograstim administration post transplant? First, some of the earlier trials used BM 1-3 instead of PBPC. The results of these studies are no longer clinically relevant, because more than 95% of all autologous transplants nowadays use mobilized PB. 17 Second, previous studies suffer from low patient numbers. The primary end point of earlier studies was the pace of hematopoietic recovery, and they were not powered to detect differences in any of the important clinical end points. The largest study reported so far intended to give G-CSF or no growth factor to 241 patients with breast cancer (from day 0 or day þ 5 until neutrophil recovery). The treatment arm without G-CSF, however, was closed after 20 patients had been recruited and patient recruitment continued for the remaining arms only. 9 This, like other studies, [4] [5] [6] [7] [8] 18 confirmed the effects of G-CSF administration on the speed of neutrophil recovery after PBPCT, but no demonstrable effect on the number of days with fever, the use of amphotericin B, or the number of positive blood cultures was seen.
Third, the trial by Hornedo et al -like most other trialssuffers from a lack of stringent definitions and guidelines, which are critical if the role of a specific intervention on the incidence of infections in neutropenic patients is being investigated. For instance, fever and infection need precise definitions agreed by all investigators. Furthermore, guidelines as to which diagnostic procedures are mandatory and which prophylactic and therapeutic measures should be taken must be agreed and acted upon in all centers. Our study accrued close to 200 patients in order to detect a difference in microbiologically defined infections between the lenograstim and the placebo group. Special emphasis was put on strictly defined diagnostic and therapeutic procedures for all study participants.
Patients on lenograstim also showed faster neutrophil recovery, needed fewer days with i.v. antibiotics, and could be discharged significantly earlier from hospital. Faster neutrophil recovery and shorter hospital stay, [4] [5] [6] [7] as well as fewer days on antibiotic therapy, 5 have also been reported by other randomized studies, but none of these demonstrated a significant difference in the incidence or severity of infections.
There is no doubt that also our study faced problems that may have influenced the results. This was a multicenter study involving 20 centers across Europe. It was therefore not possible to control for all differences in patient management and the choice of antibiotic therapy. We tried to minimize differences in clinical practice by using strict definitions and guidelines for prophylaxis and treatment. Stratification was used to correct for some differences in clinical practice such as the use of quinolone prophylaxis. To reduce problems with interpretation of microbiological and clinical findings, we asked an external expert in transplant-related infectious diseases to reevaluate the charts of all patients with documented microbiological infections. Although some reclassification occurred, the major results of the study did not change.
We conclude that the administration of lenograstim after PBPCT not only accelerates neutrophil recovery and shortens the time spent in hospital but also significantly reduces the incidence of infections and of bacteremia in particular. As this study was performed in six European countries with different health care and reimbursement systems, an economic analysis of the study results was not feasible. However, it seems highly likely that the use of less antibiotics for a shorter period of time and the earlier discharge from hospital in the lenograstim group of patients would have led to cost savings comparable to those seen in previous studies. 6 
Table 5
Causes of death on study 
